112 related articles for article (PubMed ID: 11296610)
1. Promoting the use of oral ondansetron in children receiving cancer chemotherapy.
Walker PC; Biglin KE; Constance TD; Bhambhani K; Sims-McCallum R
Am J Health Syst Pharm; 2001 Apr; 58(7):598-602. PubMed ID: 11296610
[No Abstract] [Full Text] [Related]
2. Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis?
Martin M
J Clin Oncol; 1996 Apr; 14(4):1401-2. PubMed ID: 8648398
[No Abstract] [Full Text] [Related]
3. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
Stewart DJ; Dahrouge S; Coyle D; Evans WK
J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a single 8-mg i.v. dose of ondansetron hydrochloride for preventing chemotherapy-induced emesis.
Bernstein BJ; Ong C
Am J Health Syst Pharm; 2002 Apr; 59(7):650-2. PubMed ID: 11944605
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Lachaine J; Laurier C; Langleben A; Vaillant L
Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
[No Abstract] [Full Text] [Related]
7. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
Corapçioglu F; Sarper N
Pediatr Hematol Oncol; 2005 Mar; 22(2):103-14. PubMed ID: 15804995
[TBL] [Abstract][Full Text] [Related]
8. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
[TBL] [Abstract][Full Text] [Related]
9. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
11. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
12. Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients.
Lehoczky O; Udvary J; Pulay T
Neoplasma; 2002; 49(2):126-8. PubMed ID: 12088106
[TBL] [Abstract][Full Text] [Related]
13. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
14. Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.
Freedman SB; Steiner MJ; Chan KJ
PLoS Med; 2010 Oct; 7(10):. PubMed ID: 20967234
[TBL] [Abstract][Full Text] [Related]
15. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
16. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Dempsey CL; Coop AJ; Shillington A; Farley PA; Eberhardt DR; O'Briant S
Am J Health Syst Pharm; 2004 Apr; 61(8):781-6. PubMed ID: 15127961
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic therapy in managed care oncology: roundtable discussion.
Gerbino PP; Goldsmith M; Kenney JT; Lindley C; Nolte J; Quan W; Reich PR
Med Interface; 1996 Sep; Suppl C():16-35. PubMed ID: 10161507
[TBL] [Abstract][Full Text] [Related]
20. Prevention of delayed emesis caused by chemotherapy.
Copur MS; Ledakis P; Norvell M
N Engl J Med; 2000 Sep; 343(12):888-9; author reply 889-90. PubMed ID: 11001694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
